BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11972511)

  • 1. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
    Yi Q; Desikan R; Barlogie B; Munshi N
    Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
    Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
    Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
    Hájek R; Butch AW
    Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
    Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
    Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL
    Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
    Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
    Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
    Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
    Lim SH; Bailey-Wood R
    Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma.
    Garderet L; Mazurier C; Pellat-Deceunynck C; Karim A; Baudin B; Funck-Brentano C; Bouchet S; Geffroy A; Bataille R; Gorin NC; Lopez M
    Leuk Lymphoma; 2006 Jul; 47(7):1340-7. PubMed ID: 16923566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
    Osterborg A; Henriksson L; Mellstedt H
    Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.
    Jung SH; Lee HJ; Lee YK; Yang DH; Kim HJ; Rhee JH; Emmrich F; Lee JJ
    Oncotarget; 2017 Jun; 8(25):41538-41548. PubMed ID: 28088784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.